Editas Medicine prices $125M public offering of 12.5M shares at $10.00/share

Editas Medicine, Inc.

Offering of 12,500,000 shares at $10.00 per share; gross proceeds ~$125 million.
Underwriters granted 30-day option to purchase up to an additional 1,875,000 shares.
Net proceeds estimated at ~$117.2 million, or ~$134.9 million if option fully exercised.
Closing expected on or about June 20, 2023; J.P. Morgan, Cowen, and Evercore lead.
Proceeds will support clinical-stage genome editing pipeline development.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Editas Medicine, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. valued at approximately $117.2 million (effective 2023-06-14).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C.
Value: approximately $117.2 million
Effective: 2023-06-14

Exact text from the filing

On June 14, 2023, Editas Medicine, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering of 12,500,000 shares (the “Underwritten Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

View on SEC.gov

Browse all material agreements →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-011141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.